Genomic First Testing in Chronic Kidney Disease (NCT06794567)
Improving Diagnosis for Genetic Kidney Disease Through Early Genomic Assessment
🩺 Plain-English Summary (8th-Grade Level)
This multi-center study examines the role of genetic testing in patients with chronic kidney disease (CKD) who are identified as being at risk for genetic kidney disease, based on Ontario Health's Provincial Genetic Program (OH-PGP) guidelines. Participants will be assigned to either genome-wide sequencing or standard genetic testing, depending on when they were initially diagnosed with kidney disease. To evaluate the impact of genetic testing, patients and caregivers will complete quality-of-life questionnaires before and after testing. Participants may also choose to take part in a one-on-one interview at the end of the study to provide additional insights. They will have the option to link their data to the Institute for Clinical Evaluative Sciences (ICES), allowing researchers to explore health outcomes such as the costs of genetic testing and healthcare resource use. Family members of participants will be invited to provide DNA samples to help identify genetic changes in the affected individual. Referring physicians will complete a survey to assess the clinical value of genetic testing for each patient they refer. We will perform an economic analysis comparing the genome wide sequencing to the standard genetic testing group. The study's findings will offer important guidance on how genetic testing influences patient care, clinical outcomes, and the timing of genomic assessments in managing CKD.
Who can join: Review the eligibility criteria below.
Location: London Health Sciences Centre — London, Ontario
🧪 Interventions in This Study
- Genetic Testing (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- London Health Sciences Centre — London, Ontario
📞 Contact the Study Coordinator
Phone: (519) 685-8500
Email: dervla.connaughton@lhsc.on.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Kidney Disease(CKD)
- Effect of Oral Consumption of a Symbiotic Gelatin on the Presence of Gastrointestinal Symptoms and Quality of Life in People With Chronic Kidney Disease — Toluca,
- Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD) — Birmingham, Alabama
- Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease — Cleveland, Ohio
- Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2) — Birmingham, Alabama
- An Intervention to Reduce Sedentary Behavior for Adults With Chronic Kidney Disease — Chicago, Illinois
Explore by condition: All Chronic Kidney Disease(CKD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.